Arvinas plans preliminary Phase 1 data presentation for lymphoma drug ARV-393 at ASH 2026
ARVN•Arvinas plans to present preliminary Phase 1 results for ARV-393 at the American Society of Hematology meeting on December 14, 2026. The presentation will cover safety and drug activity in relapsed or refractory non-Hodgkin lymphoma, including preliminary efficacy findings in T-cell lymphomas.
1. Planned presentation
Arvinas will present preliminary Phase 1 results for its oral BCL6 degrader ARV-393 (zaloblideg) at the American Society of Hematology meeting on December 14, 2026. The trial evaluates the drug in patients with relapsed or refractory non-Hodgkin lymphoma, and the presentation will cover safety and drug activity across patients, with preliminary efficacy findings in T-cell lymphomas.
